Gritstone bio

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Our mission is to improve the lives of patients by developing personalized medicines for cancer that leverage powerful insights from our genomic and immune profiling technologies. By applying the most advanced data science approaches and leveraging cutting-edge biology, we aim to understand how tumors escape the immune system and develop therapies to overcome them.

At Gritstone, we strive to bring the promise of personalized medicine to cancer patients worldwide by unleashing the power of the immune system. Our goal is to become the go-to biotechnology company, providing innovative treatments filled with insights never available before.

Gritstone Oncology has been awarded numerous awards and accolades including the The 45th SCRIP award for “Best Company in Immuno-Oncology”, TIME Magazine Top 100 Most Influential Companies, and 2017 Fierce 15 Award.